


ABSTRACT OF THE DISCLOSURE

This invention provides compounds defined by Formula I

5



I

or a pharmaceutically acceptable salt thereof,
wherein R¹, Q, Y¹, Y², Y³, and R² are as defined in the specification. The
invention also provides pharmaceutical compositions comprising a compound of
Formula I, or a pharmaceutically acceptable salt thereof, as defined in the
10 specification, together with a pharmaceutically acceptable carrier, diluent, or
excipient. The invention also provides methods of inhibiting an MMP-13 enzyme
in an animal, comprising administering to the animal a compound of Formula I, or
a pharmaceutically acceptable salt thereof. The invention also provides methods
of treating a disease mediated by an MMP-13 enzyme in a patient, comprising
15 administering to the patient a compound of Formula I, or a pharmaceutically
acceptable salt thereof, either alone or in a pharmaceutical composition. The
invention also provides methods of treating diseases such as heart disease,
multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or
rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart
20 failure, age-related macular degeneration, chronic obstructive pulmonary disease,
asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a
patient, comprising administering to the patient a compound of Formula I, or a
pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical
composition. The invention also provides combinations, comprising a compound
25 of Formula I, or a pharmaceutically acceptable salt thereof, together with another
pharmaceutically active component as described in the specification.